Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
OTC:LMMY Dr. Marvin Hausman, an esteemed Immunologist and Board-Certified Urological Surgeon. With more than five decades of experience in drug research.
-
Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026Topline results from Phase 2 VISTA trial of ML-007C-MA for Alzheimer’s disease psychosis...
-
MALVERN, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for...
-
Internationally recognized radiopharmaceutical leader joins Actithera as the lead FAP-targeting asset advances to clinical development and the differentiated pipeline takes shapeBrings over 15 years...
-
LAMY, to become Exousia Bio, Inc. (OTCPINK: LMMY) announced the completion of the acquisition of 100% of Exousia AI, Inc. in an all-stock transaction.
-
LAMY, to become Exousia Bio, Inc. (OTCPINK: LMMY) announced the completion of the acquisition of 100% of Exousia AI, Inc. in an all-stock transaction.
-
Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The "Glycomics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarkets.com's...
-
Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The "Biobanks Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" has been added to ResearchAndMarkets.com's offering. ...
-
Sangamo Therapeutics today announced that the FDA has granted Fast Track Designation to ST-503 in chronic neuropathic pain
-
The collaboration unites complementary scientific and technical expertise to provide seamless solutions across the biopharmaceutical value chainClients to benefit from accelerated timelines, as well...